» Articles » PMID: 29082457

Systematic Analysis Reveals a LncRNA-mRNA Co-expression Network Associated with Platinum Resistance in High-grade Serous Ovarian Cancer

Overview
Publisher Springer
Specialty Oncology
Date 2017 Oct 31
PMID 29082457
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Resistance to platinum-based chemotherapy is the major barrier to treating high-grade serous ovarian cancer (HGS-OvCa). To improve HGS-OvCa patient prognosis, it is critical to identify the underlying mechanisms that promote platinum resistance. The goal of the present study was to identify a lncRNA-mRNA co-expression network and key lncRNAs that predict resistance to platinum-based chemotherapy in ovarian cancer patients. By systematically analyzing the expression profiles of lncRNAs and mRNAs in HGS-OvCa samples from the Cancer Genome Atlas (TCGA), we revealed that lncRNAs play important roles in platinum resistance in HGS-OvCa patients and delineate a lncRNA-mRNA co-expression network in HGS-OvCa patients who exhibit platinum resistance. Within the platinum resistance-specific lncRNA-mRNA network, 35 lncRNAs and 270 mRNAs showed 124 significant lncRNA-mRNA co-expression relationships. Pathway analysis revealed that lncRNAs in the platinum resistance network may participate in platinum resistance by regulating metabolic pathways. Moreover, HGS-OvCa patients with low lncRNA RP5-1120P11.1 expression showed a poorer prognosis than those with high lncRNA RP5-1120P11.1 expression in TCGA dataset (P = 2.74 × 10, log rank test), which was also validated in the GSE63885 dataset (P = 0.0242, log rank test). Network and function analysis revealed that lncRNA RP5-1120P11.1 regulates many cancer-related signaling pathways, such as the PI3K-AKT signaling pathway (P = 1.02 × 10, hypergeometric test) and the Jak-STAT signaling pathway (P = 1.71 × 10, hypergeometric test). Particularly, lncRNA RP5-1120P11.1 expression is significantly positively correlated with ABCC10 gene expression (P = 3.89 × 10, Pearson correlation test). Both lncRNA RP5-1120P11.1 and ABCC10 were down-regulated in platinum-resistant HGS-OvCa patients, and RP5-1120P11.1 is located near ABCC10 on chromosome 6. Gene ABCC10 has been implicated in resistance to docetaxel treatment. The present study paves the way for investigating lncRNA functions in platinum drug resistance and identifying lncRNAs with prognostic and therapeutic potential in HGS-OvCa.

Citing Articles

Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer.

Xu W, Sang S, Wang J, Guo S, Zhang X, Zhou H Front Immunol. 2024; 15:1452946.

PMID: 39355254 PMC: 11442270. DOI: 10.3389/fimmu.2024.1452946.


Unraveling the Mechanism of Curculiginis Rhizoma in Suppressing Cisplatin Resistance in Non-Small Cell Lung Cancer: An Experimental Study.

Huang X, Wang M, Zhu B, Hao Y, Gao R, Liu W Onco Targets Ther. 2024; 17:471-487.

PMID: 38895133 PMC: 11182732. DOI: 10.2147/OTT.S448636.


Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.

Wang H, Li Y, Wang Y, Shang X, Yan Z, Li S J Gynecol Oncol. 2023; 35(2):e13.

PMID: 37921598 PMC: 10948987. DOI: 10.3802/jgo.2024.35.e13.


Testing lncRNAs signature as clinical stage-related prognostic markers in gastric cancer progression using TCGA database.

Beeraka N, Gu H, Xue N, Liu Y, Yu H, Liu J Exp Biol Med (Maywood). 2022; 247(8):658-671.

PMID: 35068210 PMC: 9039491. DOI: 10.1177/15353702211067173.


Emerging role of circulating tumor cells in immunotherapy.

Rzhevskiy A, Kapitannikova A, Malinina P, Volovetsky A, Aboulkheyr Es H, Kulasinghe A Theranostics. 2021; 11(16):8057-8075.

PMID: 34335980 PMC: 8315079. DOI: 10.7150/thno.59677.